Literature DB >> 33322697

An Inside Job: Applications of Intracellular Single Domain Antibodies.

Eline Soetens1,2, Marlies Ballegeer1,2, Xavier Saelens1,2.   

Abstract

Sera of camelid species contain a special kind of antibody that consists only of heavy chains. The variable antigen binding domain of these heavy chain antibodies can be expressed as a separate entity, called a single domain antibody that is characterized by its small size, high solubility and oftentimes exceptional stability. Because of this, most single domain antibodies fold correctly when expressed in the reducing environment of the cytoplasm, and thereby retain their antigen binding specificity. Single domain antibodies can thus be used to target a broad range of intracellular proteins. Such intracellular single domain antibodies are also known as intrabodies, and have proven to be highly useful tools for basic research by allowing visualization, disruption and even targeted degradation of intracellular proteins. Furthermore, intrabodies can be used to uncover prospective new therapeutic targets and have the potential to be applied in therapeutic settings in the future. In this review we provide a brief overview of recent advances in the field of intracellular single domain antibodies, focusing on their use as research tools and potential therapeutic applications. Special attention is given to the available methods that allow delivery of single domain antibodies into cells.

Entities:  

Keywords:  delivery methods; intrabody; research tool; single domain antibody; therapy

Year:  2020        PMID: 33322697      PMCID: PMC7764588          DOI: 10.3390/biom10121663

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  175 in total

1.  Cell surface adherence and endocytosis of protein transduction domains.

Authors:  Mathias Lundberg; Sara Wikström; Magnus Johansson
Journal:  Mol Ther       Date:  2003-07       Impact factor: 11.454

2.  Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo.

Authors:  Friedrich Koch-Nolte; Jan Reyelt; Britta Schössow; Nicole Schwarz; Felix Scheuplein; Stefan Rothenburg; Friedrich Haag; Vanina Alzogaray; Ana Cauerhff; Fernando A Goldbaum
Journal:  FASEB J       Date:  2007-06-15       Impact factor: 5.191

3.  Antibody scFv fragments without disulfide bonds made by molecular evolution.

Authors:  K Proba; A Wörn; A Honegger; A Plückthun
Journal:  J Mol Biol       Date:  1998-01-16       Impact factor: 5.469

4.  Targeting RyR2 with a phosphorylation site-specific nanobody reverses dysfunction of failing cardiomyocytes in rats.

Authors:  Tian Li; Yafeng Shen; Fangxing Lin; Wenyan Fu; Shuowu Liu; Chuqi Wang; Jizhou Liang; Xiaoyan Fan; Xuting Ye; Ying Tang; Min Ding; Yongji Yang; Changhai Lei; Shi Hu
Journal:  FASEB J       Date:  2019-03-18       Impact factor: 5.191

5.  The introduction of proteins into mammalian cells by electroporation.

Authors:  W F Morgan; J P Day
Journal:  Methods Mol Biol       Date:  1995

Review 6.  Pathogenesis and control of the Chinese highly pathogenic porcine reproductive and respiratory syndrome virus.

Authors:  Jun Han; Lei Zhou; Xinna Ge; Xin Guo; Hanchun Yang
Journal:  Vet Microbiol       Date:  2017-03-02       Impact factor: 3.293

7.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

Authors:  Erwin De Genst; Karen Silence; Klaas Decanniere; Katja Conrath; Remy Loris; Jörg Kinne; Serge Muyldermans; Lode Wyns
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

8.  A one-step exclusion-binding procedure for the purification of functional heavy-chain and mammalian-type gamma-globulins from camelid sera.

Authors:  Michel R Blanc; Abdelhaq Anouassi; Mohanad Ahmed Abed; Guillaume Tsikis; Sylvie Canepa; Valérie Labas; Maya Belghazi; Gilles Bruneau
Journal:  Biotechnol Appl Biochem       Date:  2009-11-18       Impact factor: 2.431

9.  Humanized-VH/VHH that inhibit HCV replication by interfering with the virus helicase activity.

Authors:  Aninthita Phalaphol; Kanyarat Thueng-In; Jeeraphong Thanongsaksrikul; Ornnuthchar Poungpair; Kunan Bangphoomi; Nitat Sookrung; Potjanee Srimanote; Wanpen Chaicumpa
Journal:  J Virol Methods       Date:  2013-09-12       Impact factor: 2.014

10.  Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.

Authors:  Aymeric Chartier; Vered Raz; Ellen Sterrenburg; C Theo Verrips; Silvère M van der Maarel; Martine Simonelig
Journal:  Hum Mol Genet       Date:  2009-03-03       Impact factor: 6.150

View more
  6 in total

1.  A Cell-free Expression Pipeline for the Generation and Functional Characterization of Nanobodies.

Authors:  Lisa Haueis; Marlitt Stech; Stefan Kubick
Journal:  Front Bioeng Biotechnol       Date:  2022-04-28

2.  Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure.

Authors:  Erwin De Genst; Kylie S Foo; Yao Xiao; Eduarde Rohner; Emma de Vries; Jesper Sohlmér; Nevin Witman; Alejandro Hidalgo; Terje R S Kolstad; William E Louch; Susanne Pehrsson; Andrew Park; Yasuhiro Ikeda; Xidan Li; Lorenz M Mayr; Kate Wickson; Karin Jennbacken; Kenny Hansson; Regina Fritsche-Danielson; James Hunt; Kenneth R Chien
Journal:  Nat Commun       Date:  2022-05-31       Impact factor: 17.694

Review 3.  Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments.

Authors:  Mehdi Arbabi-Ghahroudi
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

4.  Evaluation and selection of potent fluorescent immunosensors by combining fluorescent peptide and nanobodies displayed on yeast surface.

Authors:  Akihito Inoue; Takanobu Yasuda; Bo Zhu; Tetsuya Kitaguchi; Akikazu Murakami; Hiroshi Ueda
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

5.  AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model.

Authors:  Marika Marino; Lujia Zhou; Melvin Y Rincon; Zsuzsanna Callaerts-Vegh; Jens Verhaert; Jérôme Wahis; Eline Creemers; Lidia Yshii; Keimpe Wierda; Takashi Saito; Catherine Marneffe; Iryna Voytyuk; Yessica Wouters; Maarten Dewilde; Sandra I Duqué; Cécile Vincke; Yona Levites; Todd E Golde; Takaomi C Saido; Serge Muyldermans; Adrian Liston; Bart De Strooper; Matthew G Holt
Journal:  EMBO Mol Med       Date:  2022-03-30       Impact factor: 12.137

Review 6.  AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System.

Authors:  Marika Marino; Matthew G Holt
Journal:  Front Neurol       Date:  2022-04-12       Impact factor: 4.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.